Navigation Links
Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
Date:10/27/2010

had received at least one prior therapy and five patients were treated in the first-line setting.(1)  This Part 2 expansion cohort study of patients with ALK-positive advanced NSCLC, independent of the number of previous chemotherapies, followed the completion of the dose-escalation study which enrolled 37 advanced cancer patients with various tumors, including NSCLC, colorectal, pancreatic and inflammatory myofibroblastic tumor (IMT) tumors.(8)

These data were previously presented at the 2010 American Society of Clinical Oncology Annual Meeting.(7)

About Crizotinib (PF-02341066)

Crizotinib (PF-02341066) is a first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,(3) and is representative of Pfizer's personalized medicine approach to cancer treatment.  By inhibiting ALK, crizotinib (PF-02341066) blocks signaling in a number of cell pathways that may be critical for the growth and survival of tumor cells.(4)  Crizotinib (PF-02341066) is also an inhibitor of c-MET (mesenchymal endothelial transition factor).(3)

About Non-Small Cell Lung Cancer

Lung cancer is one of the most common cancers worldwide.(9)  NSCLC accounts for about 85 percent of lung cancer cases and remains difficult to treat, particularly in the metastatic setting. Approximately 75 percent of NSCLC patients are diagnosed late with metastatic, or advanced, disease, where the five-year survival rate is only 6 percent.(10,11)  In addition, the current standard of care for advanced NSCLC demonstrates a response rate of only about 15 percent.(12)  Approximately 3-5 percent of NSCLC tumors are ALK-positive.(4)

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
4. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
5. Tapestry Reports Second Quarter 2007 Results
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... , Sept. 1, 2014 Reportbuyer.com ... Rigid Transparent Plastics: Global Markets ... INTRODUCTION This chapter ... describing the study goals and objectives, reasons ... methodology, information sources and analyst credentials, and ...
(Date:8/30/2014)... 30, 2014   Royal Philips  (NYSE: PHG, AEX: ... a new ultrasound system designed to enable global hospitals ... patient volumes and cost pressures. Making its debut at ... Barcelona this week, Affiniti provides ... with fewer resources deliver high quality patient care. ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Rigid Transparent Plastics: Global Markets Outside North America 2Rigid Transparent Plastics: Global Markets Outside North America 3Rigid Transparent Plastics: Global Markets Outside North America 4Rigid Transparent Plastics: Global Markets Outside North America 5Rigid Transparent Plastics: Global Markets Outside North America 6Rigid Transparent Plastics: Global Markets Outside North America 7Rigid Transparent Plastics: Global Markets Outside North America 8Rigid Transparent Plastics: Global Markets Outside North America 9Rigid Transparent Plastics: Global Markets Outside North America 10Rigid Transparent Plastics: Global Markets Outside North America 11Rigid Transparent Plastics: Global Markets Outside North America 12Rigid Transparent Plastics: Global Markets Outside North America 13Rigid Transparent Plastics: Global Markets Outside North America 14Rigid Transparent Plastics: Global Markets Outside North America 15Rigid Transparent Plastics: Global Markets Outside North America 16Rigid Transparent Plastics: Global Markets Outside North America 17Rigid Transparent Plastics: Global Markets Outside North America 18Rigid Transparent Plastics: Global Markets Outside North America 19Rigid Transparent Plastics: Global Markets Outside North America 20Rigid Transparent Plastics: Global Markets Outside North America 21Rigid Transparent Plastics: Global Markets Outside North America 22Rigid Transparent Plastics: Global Markets Outside North America 23Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4Implementing a Strategic Thought Leader Management & Engagement System 2
... of GDIR Agonists Under its ... Partnership ... Inc.,(Nasdaq: ARNA ) announced today that initial clinical study ... being investigated,for the treatment of type 2 diabetes under a ...
... following 4 weeks of, treatment with R7128 1500mg and Pegasys(R) plus Copegus(R) ... tolerability comparable to placebo ... Conference Call Scheduled for 4:00PM ET Today -, PRINCETON, N.J., Jan. ... a 4-week Phase 1,clinical trial to evaluate two oral dose levels of ...
Cached Medicine Technology:Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 2Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 3Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 2Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 3Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 4Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 5Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C 6
(Date:9/2/2014)... Falls, New York (PRWEB) September 02, 2014 ... ?” This is the question that millions of people ... among health care providers, patients and their families or ... to misdiagnosis due to its distinct similarities to other ... dermatitis, impetigo, bed bug bites, eczema, varicella and many ...
(Date:9/2/2014)... September 02, 2014 Michigan’s health care ... Care Act and the Healthy Michigan Plan. Throughout these ... remains a trusted funding resource for under-served individuals. Federal ... uninsured or underinsured women between the ages of 50 ... 250 percent of the federal poverty level. ...
(Date:9/2/2014)... Recently, Os-Monitor.com, an innovative company that provides ... collection of employee internet monitoring products ( http://www.os-monitor.com ). ... up to 10% off, on these useful items. ... than 20 different kinds of high end monitoring programs ... for companies of all sizes. With its high end ...
(Date:9/2/2014)... Barcelona, Spain Tuesday 2 September 2014: A simple ... atrial fibrillation (AF), according to research presented at ESC ... Professor Davy said: "Atrial fibrillation (AF) is the most ... failure risk by three-fold and the risk of stroke ... stroke in 1 of 4 cases. However, AF is ...
(Date:9/2/2014)... California (PRWEB) September 02, 2014 Developers ... have announced a new ProIntro Lesson from Pixel Film ... create easy and fresh-looking titles,” said Christina Austin, CEO ... and armature, ProIntro is a definite game changer.” , ... the ProIntro Lesson from Pixel Film Studios. ProIntro is ...
Breaking Medicine News(10 mins):Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Useful Employee Internet Monitoring Products Now For Sale At Os-Monitor.com 2Health News:Simple awareness campaign in general practice identifies new cases of AF 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios Released a New ProIntro Lesson Exclusively for Final Cut Pro X 3
... been sent to people traveling to the Indian Ocean. ... bites.// ,93 cases have been reported by ... last year’s average of 6. ,According to the HPA's ... had cases of mosquito-borne virus.,Insect repellents, long trousers and ...
... of the awareness of obesity epidemic afflicting the kids in ... of these actions is not up to the mark. ... Progress in Preventing Childhood Obesity: How Do We Measure Up?, ... ,"The very health of the country hangs in ...
... “crisis” over lack of donors at sperm bank clinics. According to ... stock//, women and couples wanting to have children were facing a ... was 459. Ever since, the number had been decreasing. To make ... kids the right to know the identity of their donor father ...
... start by next week the distribution of a drug to ... ,South Africa is being affected by an extremely virulent ... 52 people in the country. The health officials have now ... early as next week to help fight the disease. The ...
... US is asking for an extensive study for the evaluation ... the use of stents. // ,Stents are widely ... eluting stents are had essentially eliminated short-term restenosis as a ... come under a cloud for possible late-term risks. Reports indicate ...
... In a unique way to curb binge drinking, researchers say parents ... that allowing youngsters // to drink at parties and at home ... ,Professor Mark Bellis, the author of the report said ... in moderation and allowed to drink with them were sensible in ...
Cached Medicine News:Health News:Slow Fight Against Childhood Obesity 2Health News:Slow Fight Against Childhood Obesity 3Health News:Shortage of donors at sperm bank clinics 2Health News:South Africa To Make Available Two New Drugs To Fight The TB Outbreak 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: